---
layout: post
title: "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing"
date: 2026-02-05 18:35:13 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-00013
original_published: 2023-01-06 00:00:00 +0000
significance: 8.00
---

# Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** January 06, 2023 00:00 UTC
**Document Number:** 2023-00013

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/01/06/2023-00013/agency-information-collection-activities-submission-for-office-of-management-and-budget-review)
- API: https://www.federalregister.gov/api/v1/documents/2023-00013

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
